Pilot Study to Evaluate Deep Brain Stimulation (DBS) of the Nucleus Accumbens (NAc) for Patients With Treatment-refractory Opioid Use Disorder

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a pilot study to evaluate the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAc) as adjunctive treatment for treatment-refractory opioid use disorder. This study will include 3 individuals with opioid use disorder and relapsing opioid use despite active participation in a drug addiction treatment program.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Maximum Age: 65
Healthy Volunteers: f
View:

• Male and females age ≥ 22 years with diagnosis of opioid use disorder (OUD) based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) with at least a 5-year history

• OUD must be the primary disorder

• Failed at least two levels of treatment (Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient COAT, residential, inpatient, alternative to intensive outpatient program, Drug Dependence Unit, which included buprenorphine/naloxone or buprenorphine monotherapy.

• Has exhibited more than 2 episodes of opioid use relapse in prior 12 months despite ongoing participation in MAT program, including either methadone or buprenorphine or suboxone

• No active ilicit substance abuse as based on urine testing

• Has completed a neuro-psychological evaluation to the satisfaction of a neuropsychologist

• Has completed a psychiatric evaluation to the satisfaction of a psychiatrist

• Has had a brain MRI performed and reviewed by neurosurgeon with no contraindication for DBS procedure identified

• Platelet count \> 125,000 per cubic mm and prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits

⁃ Negative blood cultures to rule out bacteremia

Locations
United States
Pennsylvania
AHN Allegheny General Hospital
RECRUITING
Pittsburgh
Contact Information
Primary
Nestor Tomycz, MD
nestor.tomycz@ahn.org
412-359-6200
Backup
Donald Whiting, MD
donald.whiting@ahn.org
412-359-6200
Time Frame
Start Date: 2022-02-07
Estimated Completion Date: 2026-12
Participants
Target number of participants: 3
Treatments
Experimental: NAc DBS
Subjects will receive bilateral DBS of the NAc
Sponsors
Leads: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Collaborators: Abbott

This content was sourced from clinicaltrials.gov